NASDAQ · PHAR
Pharming Group N.V. ADS, each representing 10
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for PHAR has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $0.07 | $0.15 | $-0.01 | 2 |
| Mar 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Jun 2027 | $0.00 | $0.00 | $0.00 | 1 |
| Sep 2027 | $0.00 | $0.00 | $0.00 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · MarketBeat · Fintel · RTTNews- The Motley Fool · Oct 27, 1:30 PM EDTPharming (PHAR) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Oct 27, 11:05 AM EDTPharming Group Q3 Earnings Call HighlightsPharming Group (NASDAQ:PHAR) reported third-quarter revenue growth of 21% to $117.6 million, supported by higher sales of its RUCONEST hereditary angioedema treatment and Joenja therapy for activated phosphoinositide 3-kinase delta syndrome, or APDS. Kenneth Lynard, interim co-C
- Fintel · Oct 27, 10:23 AM EDTPharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in NovemberPharming Group N.V. reported its third quarter 2026 financial results, with total revenues increasing by 21% to US$117.6 million, compared to US$97.3 million in the third quarter of 2025. RUCONEST revenues amounted to US$93.8 million, a 14% increase compared to the third quarter
- RTTNews · Oct 27, 3:48 AM EDTPharming Q3 Revenue Jumps 21%, CVID Data Due In November(RTTNews) – Pharming Group (PHAR) reported third quarter 2026 financial results, with double-digit revenue growth and higher profitability driven by continued demand for its rare disease therapies RUCONEST and Joenja.
- RTTNews · Oct 22, 2:29 AM EDTPharming Group Q3 Prel. Revenue Rises; Tightens FY26 Revenue Guidance(RTTNews) – Pharming Group N.V. (PHGUF.PK, PHGUF.OB, PHAR, PHARM.AS), a Netherlands-based biotechnology company focused on rare immune and genetic diseases, on Thursday reported increased preliminary revenue for the third quarter of fiscal 2026, driven by higher revenue from its
- RTTNews · Oct 14, 3:40 AM EDTPharming's Leniolisib Shows Promise Beyond APDS In Rare Genetic Immune Disorders(RTTNews) – Pharming Group N.V. (PHAR) reported positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies associated with altered PI3Kdelta signaling.
- RTTNews · Oct 14, 3:02 AM EDTPharming Reports Positive Phase II Data For Leniolisib In Rare Genetic Immune Disorders(RTTNews) – On Wednesday, Pharming Group N.V. (PHAR) announced positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation linked to altered PI3Kdelta signa
- RTTNews · Sep 25, 12:09 PM EDTFDA Accepts Pharming's SNDA For Lower-Dose Joenja In Children With APDS(RTTNews) – Pharming Group N.V. (PHAR) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval of lower doses of Joenja (leniolisib) for children aged 4 years and older who weigh between 13 kg and 27 kg
- RTTNews · Sep 11, 4:54 PM EDTPharming Gets FDA Approval For Joenja In Children With APDS(RTTNews) – Pharming Group N.V. (PHARM.AS) said the U.S. Food and Drug Administration has approved Joenja (leniolisib) for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome, or APDS, who weigh at least 27 kg.
- RTTNews · Aug 13, 3:15 AM EDTPharming Launches Joenja In Japan For APDS(RTTNews) – Pharming Group (PHAR) announced the commercial launch of Joenja (leniolisib) in Japan for adult and children aged 4 years and older with activated PI3K delta syndrome, following its inclusion in NHI price list.
- The Motley Fool · Aug 3, 8:15 PM EDTPharming (PHAR) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Jul 31, 9:32 AM EDTPharming Q2 Profit Falls On Lower Revenue; Revises FY26 Guidance(RTTNews) – Pharming Group N.V. (PHAR) reported a preliminary second-quarter results, with a sharp fall in net profit, compared to the prior year. Revenues were reduced by 3.2 percent from the previous year. The company revised its full-year guidance and expects revenue to stabil
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Pharming Group N.V. ADS, each representing 10 from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.